MLV & Co. Initiates Evoke Pharma At Hold
Analysts at MLV & Co. initiated coverage on Evoke Pharma (NASDAQ: EVOK) with a Buy rating.
The target price for Evoke Pharma is set to $12.50.
Evoke Pharma shares have dropped 31.96% over the past 52 weeks, while the S&P 500 index has gained 14.72% in the same period.
Evoke Pharma's shares rose 0.15% to close at $6.62 yesterday.
Latest Ratings for EVOK
Date | Firm | Action | From | To |
---|---|---|---|---|
Jun 2020 | HC Wainwright & Co. | Upgrades | Neutral | Buy |
Mar 2019 | HC Wainwright & Co. | Downgrades | Buy | Neutral |
Oct 2017 | FBR Capital | Reinstates | Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: MLV & Co.Initiation Analyst Ratings